George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.35
Bid: 1.30
Ask: 1.40
Change: 0.125 (10.20%)
Spread: 0.10 (7.692%)
Open: 1.225
High: 1.35
Low: 1.20
Prev. Close: 1.225
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Jun 2023 10:55

RNS Number : 3509B
Shield Therapeutics PLC
01 June 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Shield Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

W. Health L.P. ("Inventages")

City and country of registered office (if applicable)

The Bahamas

4. Full name of shareholder(s) (if different from 3.) v

Name

CGWL Nominees Limited

City and country of registered office (if applicable)

London, UK

5. Date on which the threshold was crossed or reached vi:

16 March 2023 (prior to AOP loan conversion)

6. Date on which issuer notified (DD/MM/YYYY):

25 May 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

0%

0%

0%

0%

Position of previous notification (if

applicable)

9.56%

0

9.56%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYV81293

0

0

0%

0%

SUBTOTAL 8. A

0

0%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

x

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

Vevey, Switzerland

Date of completion

31 May 2023

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFBMLTMTIMMRJ
Date   Source Headline
16th Apr 20247:00 amRNSNotice of Results
21st Feb 20247:00 amRNSUnaudited Full Year Trading Update
9th Jan 20247:00 amRNSAppointment of new Chief Financial Officer
7th Dec 20237:00 amRNSQ3 2023 U.S. Commercial Highlights
27th Nov 20235:24 pmRNSPDMR Transaction Notification
15th Nov 20237:30 amEQSHardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team
20th Oct 202311:45 amRNSAbstract to be presented at Healthcare Conference
12th Oct 20237:00 amRNSChief Financial Officer Transition
3rd Oct 20233:00 pmRNSResult of REX Retail Offer
3rd Oct 20237:00 amRNSBlock listing Interim Return
3rd Oct 20237:00 amRNSCompletion of SWK Financing
28th Sep 202312:50 pmRNSSuccessful completion of US$6.1m Equity Fundraise
28th Sep 20237:02 amRNSREX Retail Offer
28th Sep 20237:01 amRNS$20m secured debt facility &proposed equity raise
28th Sep 20237:00 amRNSInterim results update and business update
6th Sep 20237:00 amRNSNotice of Results and Change in reporting currency
25th Jul 20239:45 amEQSHardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
24th Jul 20232:27 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSBusiness Update and U.S. Q2 2023 Highlights
28th Jun 20235:30 pmRNSResults of 2023 Annual General Meeting
16th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
15th Jun 20234:35 pmRNSLapse of Offer
15th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
15th Jun 20237:00 amRNSAcceptance Level Update
14th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
14th Jun 20237:00 amRNSAcceptance Level Update
13th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
13th Jun 20237:00 amRNSAcceptance Level Update
12th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
12th Jun 20237:00 amRNSAcceptance Level Update
9th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th Jun 20237:00 amRNSAcceptance Level Update
8th Jun 202312:31 pmRNSForm 8.3 - Shield Therapeutics PLC (amendment)
8th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
8th Jun 20237:00 amRNSAcceptance Level Update
7th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
6th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
6th Jun 202310:10 amRNSGrant of share options to the CEO
5th Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
2nd Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
1st Jun 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
1st Jun 202311:00 amRNSHolding(s) in Company
1st Jun 202310:55 amRNSHolding(s) in Company
31st May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
31st May 20237:00 amRNSTotal Voting Rights
30th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
26th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
25th May 20234:44 pmRNSPublication and posting of Offer Document
25th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
24th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.